HUE052441T2 - Intranazális készítmények neurológiai és neurodegeneratív betegségekre és zavarokra - Google Patents

Intranazális készítmények neurológiai és neurodegeneratív betegségekre és zavarokra

Info

Publication number
HUE052441T2
HUE052441T2 HUE15848100A HUE15848100A HUE052441T2 HU E052441 T2 HUE052441 T2 HU E052441T2 HU E15848100 A HUE15848100 A HU E15848100A HU E15848100 A HUE15848100 A HU E15848100A HU E052441 T2 HUE052441 T2 HU E052441T2
Authority
HU
Hungary
Prior art keywords
neurological
disorders
neurodegenerative diseases
intranasal preparations
intranasal
Prior art date
Application number
HUE15848100A
Other languages
English (en)
Hungarian (hu)
Inventor
Timothy Matthias Morgan
Original Assignee
Lachesis Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014903944A external-priority patent/AU2014903944A0/en
Application filed by Lachesis Biosciences Ltd filed Critical Lachesis Biosciences Ltd
Publication of HUE052441T2 publication Critical patent/HUE052441T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE15848100A 2014-10-03 2015-09-30 Intranazális készítmények neurológiai és neurodegeneratív betegségekre és zavarokra HUE052441T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2014903944A AU2014903944A0 (en) 2014-10-03 Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Publications (1)

Publication Number Publication Date
HUE052441T2 true HUE052441T2 (hu) 2021-04-28

Family

ID=55629161

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15848100A HUE052441T2 (hu) 2014-10-03 2015-09-30 Intranazális készítmények neurológiai és neurodegeneratív betegségekre és zavarokra

Country Status (12)

Country Link
US (3) US10471040B2 (enrdf_load_stackoverflow)
EP (1) EP3200828B1 (enrdf_load_stackoverflow)
JP (3) JP2017530195A (enrdf_load_stackoverflow)
AU (1) AU2015327762C1 (enrdf_load_stackoverflow)
CA (1) CA2961936C (enrdf_load_stackoverflow)
DK (1) DK3200828T3 (enrdf_load_stackoverflow)
ES (1) ES2822562T3 (enrdf_load_stackoverflow)
HU (1) HUE052441T2 (enrdf_load_stackoverflow)
PL (1) PL3200828T3 (enrdf_load_stackoverflow)
PT (1) PT3200828T (enrdf_load_stackoverflow)
SM (1) SMT202000576T1 (enrdf_load_stackoverflow)
WO (1) WO2016049700A1 (enrdf_load_stackoverflow)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10471040B2 (en) * 2014-10-03 2019-11-12 Lachesis Biosciences Limited Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
ES2969301T3 (es) * 2017-02-02 2024-05-17 Otolanum Ag Composición intranasal que comprende betahistina
WO2021258150A1 (en) * 2020-06-25 2021-12-30 Lachesis Biosciences Limited Methods of treating or preventing organophosphorus poisoning
CA3193558A1 (en) * 2020-10-01 2022-04-07 Lyra Therapeutics, Inc. Osmotic drug delivery implants
CN115919767B (zh) * 2022-10-13 2023-08-11 暨南大学 卡巴拉汀鼻喷雾剂及其制备方法
CN119523898A (zh) * 2024-12-02 2025-02-28 肇庆学院 多靶点药物的经鼻给药制剂及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5733M (enrdf_load_stackoverflow) 1966-09-27 1968-01-22
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
FR2722989B1 (fr) 1994-07-29 1997-05-30 Synthelabo Utilisation de l'ifenprodil et de ses enantiomeres pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques et des maladies neurodegeneratives centrales
US6558560B2 (en) * 2001-07-27 2003-05-06 Hewlett-Packard Company Method for the fabrication of electrical contacts
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20030225031A1 (en) 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
WO2006035417A2 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
US8187570B1 (en) * 2005-01-04 2012-05-29 Gp Medical, Inc. Nanoparticles for protein drug delivery
MX2007012374A (es) * 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
PL1933809T3 (pl) * 2005-10-11 2012-09-28 Yissum Research Development Company Of The Hebrew Univ Of Jerusalem Kompozycje do dostarczania donosowego
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
KR20080097443A (ko) * 2006-02-03 2008-11-05 아바니르 파마슈티컬스 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
CA2641604A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
JP5340149B2 (ja) * 2007-06-26 2013-11-13 わかもと製薬株式会社 水性組成物
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
SA111320455B1 (ar) 2010-05-17 2014-10-16 Envivo Pharmaceuticals Inc صورة بلورية من (R)-7- كلورو -N- (كينوكليدين -3- يل) بنزو[b] ثيوفين -2- كربوكساميد هيدروكلوريد أحادي الهيدرات
US8673338B2 (en) * 2011-07-29 2014-03-18 Massachusetts Eye And Ear Infirmary Methods of delivering pharmaceutical agents
US10471040B2 (en) * 2014-10-03 2019-11-12 Lachesis Biosciences Limited Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders

Also Published As

Publication number Publication date
SMT202000576T1 (it) 2020-11-10
AU2015327762A1 (en) 2017-04-20
US20200078331A1 (en) 2020-03-12
US20170239209A1 (en) 2017-08-24
JP2022003100A (ja) 2022-01-11
JP2020090547A (ja) 2020-06-11
EP3200828A4 (en) 2018-04-25
AU2015327762B2 (en) 2020-06-25
PL3200828T3 (pl) 2021-01-25
JP2017530195A (ja) 2017-10-12
EP3200828B1 (en) 2020-08-12
JP7357571B2 (ja) 2023-10-06
ES2822562T3 (es) 2021-05-04
US10471040B2 (en) 2019-11-12
US20210145789A1 (en) 2021-05-20
EP3200828A1 (en) 2017-08-09
CA2961936A1 (en) 2016-04-07
AU2015327762C1 (en) 2020-10-22
WO2016049700A1 (en) 2016-04-07
US11911360B2 (en) 2024-02-27
US10933045B2 (en) 2021-03-02
CA2961936C (en) 2023-03-14
DK3200828T3 (da) 2020-10-12
PT3200828T (pt) 2020-10-08

Similar Documents

Publication Publication Date Title
IL248732A0 (en) Compounds for the treatment of ophthalmological diseases and disorders
HUE049014T2 (hu) Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére
HUE051488T2 (hu) Készítmények és eljárások központi idegrendszeri rendellenességek kezelésére
ME03454B (me) Terapeutski agensi za neurodegenerativne bolesti
EP3227330A4 (en) Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
PL3177723T3 (pl) Aptamery do zastosowania przeciwko chorobom związanym z autoprzeciwciałem
IL252696A0 (en) protein production
HUE052441T2 (hu) Intranazális készítmények neurológiai és neurodegeneratív betegségekre és zavarokra
EP3157631A4 (en) Neurodegenerative disease treatment
DK3122763T3 (da) Antimikrobielle peptiddendrimerer
GB201420986D0 (en) Neurodegenerative disorders
DK3164716T3 (da) Fremgangsmåde til diagnosticering af neurodegenerative sygdomme
HUE058705T2 (hu) Herbicidtolerancia-gének és eljárások ezek alkalmazására
GB201516905D0 (en) Treatment of Neurodegenerative diseases
PT3124621T (pt) Marcadores mitocondriais de doenças neurodegenerativas
GB201513845D0 (en) Neurodegenerative disorders
ZA201902689B (en) Therapeutic protein
HUE053974T2 (hu) Szemészeti gyógyászati készítmény
GB201701455D0 (en) Neurodegenerative disorders
GB201713743D0 (en) Ophthalmic probes
PL3903774T3 (pl) N,n-bis-2-merkaptoetyloizoftalamid do leczenia chorób neurodegeneracyjnych
GB201407132D0 (en) Marker for neurodegenerative disorders
HK40092417A (en) Compounds for treating ophthalmic diseases and disorders
GB201616715D0 (en) Therapeutic protein
ITUB20156017A1 (it) Collirio oftalmico